Program
NA-931
A development code. Also written as “NA-931 150 mg + no Tirzepatide”, “NA-931, dose 1, daily and orally” and “NA-931, dose2, daily and orally”.
Its studies are mostly in Obesity, led by Biomed Industries.
Furthest: phase 2, since Aug 16, 20243 company-led studies, 1 open or runningNext primary completion: Aug 15, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Biomed Industries | 31 open or running | phase 2since Aug 16, 2024 | Aug 16, 2024 | Aug 15, 2027phase 2 · NCT06732245 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 16, 2024First study: phase 2 study in Weight LossFirst studyNCT06564753 · 126 enrolled · Australia
- Sep 24, 2024Phase 1 study in OverweightNCT06615700 · 74 enrolled · Australia
- Dec 9, 2024Phase 2 study in ObesityNCT06732245 · 224 planned · United States, Australia, New Zealand
Ahead
- Aug 15, 2027Primary completion: phase 2 study in ObesityNCT06732245
TargetBeta
“NA-931 is a Quadruple Receptor Agonist for Insulin Like Growth Factor 1 (IGF-1), Glucagon-like Peptide-1 (GLP-1), Gastric Inhibitory Polypeptide (GIP) and Glucagon.”study text, by rule · the study
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06732245Obesity · United States, Australia, New Zealand | 2 | Not yet recruiting | Aug 15, 2027 | 224 |
| NCT06615700Overweight · Australia | 1 | Completed | Aug 12, 2024 | 74 |
| NCT06564753Weight Loss · Australia | 2 | Completed | Feb 27, 2025 | 126 |
How it is read
Names in the registry
- “NA-931”, 7 entries
- “NA-931 150 mg + no Tirzepatide”, 1 entry
- “NA-931, dose 1, daily and orally”, 1 entry
- “NA-931, dose2, daily and orally”, 1 entry
- “NA-931 dose 3, daily and orally”, 1 entry
Codes read as this program: NA931.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.